UNASSIGNED: e15589 Background: @entity11558 is an oral drug with alkylating activity and low @entity137 profile including no @entity1665 and scarce @entity1503 . Its activity in recurrent @entity43 is well known but new drugs with more activity have reduced its use. METHODS: We present a retrospective study with @entity11558 in @entity1 with recurrent @entity43 failing to the standard second line treatments or as maintenance after achieving a response to second line therapy. The dose used was 400 mg daily, during fourteen days every four weeks, until @entity137 or disease progression.Our objective was to evaluate the activity and @entity137 profile of @entity11558 in the second line setting of @entity43 @entity1 . RESULTS: Median age was 53years old. Eight @entity1 were treated with @entity11558 as maintenance after achieving a complete or a partial response with a standard second line regimen to prolong the PFS. 76.5% of the @entity1 have received 3 or more previous lines of chemotherapy. Excluding the eight @entity1 treated for maintenance, 33% achieved complete or partial response, 25% stable disease and 42% progression. The more frequent @entity137 were: nausea in 40% of @entity1 , other @entity344 in 40% and @entity1296 in 30%. The median PFS for all the group was 12,1 months and for the maintenance group of @entity1 18,1 months. The maintenance group has received between 4+ and 61+ cycles. CONCLUSIONS: @entity11558 is an oral drug with manageable @entity137 and with activity in @entity1 with recurrent @entity43 being another option to be considered after the standard second lines. Also can be used as a maintenance drug for @entity1 in response to prolong the PFS.

@entity11558 for recurrent XXXX or as maintenance after response to second-line therapy.

@entity1665 :: ('MESH:D000505', 'Disease') :: ['alopecia'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity344 :: ('MESH:D005767', 'Disease') :: ['gastrointestinal disorders'] @entity1503 :: ('MESH:D006402', 'Disease') :: ['hematologic toxicity'] @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness'] @entity11558 :: ('MESH:D006585', 'Chemical') :: ['altretamine', 'Altretamine']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
